MerLion completes phase I of finafloxacin study

Singapore: Following successful first-in-man phase I and two phase IIa clinical studies with the oral formulation of fin...

November 8, 2012 | Thursday | News
Changing the paradigm of drug development

Recent promising data on drug approvals in 2011 shows that there were 35 new molecular entities (NME) approved by the FD...

February 8, 2013 | Friday | Opinion
Medivir, Daewoong end hepatitis drug development

Singapore: Sweden-based Medivir has discontinued the development of its hepatitis B compound MIV-210 based on a joint de...

September 9, 2013 | Monday | News
Eisai reveals phase III results of breast cancer drug Halaven

Singapore: Eisai revealed its preliminary results from a recently completed phase III study of Halaven versus capecitabi...

July 10, 2012 | Tuesday | News
Antidepressant can treat sickle cell disease

Singapore: A study by researchers at the University of Michigan Medical School, US, found that antidepressant drug trany...

February 20, 2013 | Wednesday | News
Pharmaxis to launch cystic fibrosis drug in Europe

Singapore: Australian pharmaceutical company Pharmaxis is all set to launch Bronchitol for cystic fibrosis (CF) patients...

June 11, 2012 | Monday | News
UK firm withdraws insulin marketing applications

Singapore: UK's Marvel LifeScience, insulin marketing company, has withdrawn its application for centralized marketing a...

November 28, 2012 | Wednesday | Regulatory
Alchemia enrolls patients for cancer trial

Singapore: Alchemia has completed enrollment of patients in a pivotal phase III clinical trial evaluating its lead prod...

March 1, 2013 | Friday | News
Bayer, 5 cancer institutes set up oncology network

Sinapore: Bayer HealthCare in Singapore in collaboration with five research institutions have kaunched new Integrated Tr...

January 10, 2013 | Thursday | News
Daiichi develops antibody to prevent fracture

Singapore: Daiichi Sankyo's 24-month randomized, double-blind, placebo-controlled multi-center phase III clinical trial ...

October 16, 2012 | Tuesday | News
Gilead to halt phase III study of leukemia drug

Singapore: Gilead Sciences plans to halt phase III study evaluating idelalisib in previously-treated chronic lymphocytic...

October 10, 2013 | Thursday | News
Sihuan, NeuroVive to develop heart and brain products

Singapore: Sihuan Pharmaceutical entered into a collaboration agreement with NeuroVive Pharmaceutical to develop two in...

November 21, 2012 | Wednesday | News
Bioxyne to report COPD trial results in June

Singapore: Australian company Bioxyne closed its 320-patient study, which was designed to evaluate the efficacy and safe...

May 29, 2012 | Tuesday | News
MicuRx next gen antibiotic gets US patent

Singapore: MicuRx Pharmaceuticals, a privately-held biopharmaceutical company developing next-generation antibiotics, ha...

May 24, 2012 | Thursday | News
MedImmune, UCSF enter 3-year R&D deal

Singapore: MedImmune, the global biologics R&D arm of AstraZeneca, has entered into a three-year collaboration with ...

February 18, 2014 | Tuesday | News
Biogen to commercialize MS therapies in Asia

Singapore: Belgium based pharmaceutical company UCB and global pharmaceutical company, Biogen, have entered into an agre...

February 11, 2014 | Tuesday | News
BD launches Cell Analyzer to enhance drug discovery

Singapore: BD Biosciences, a global medical technology company, has launched BD LSRFortessa X-20 Cell Analyzer, to deliv...

July 11, 2013 | Thursday | News
Viralytics melanoma study shows +ve results

Singapore: Assistant Professor (Dr) Robert H I Andtbacka presented a summary of his ongoing study with Viralytics' Cavat...

March 25, 2013 | Monday | News